CinCor Pharma Inc – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 09/30/22 Q3

ended 06/30/22 Q2

ended 03/31/22 Q1

ended 12/31/21 FY 2021

Prospectuses and Registrations Filter

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Tender offer solicitation – amended

Third party tender offer – amended

Ownership Filter

Sofinnova Capital IX

Sofinnova Venture Partners X, L.P.

Schwab Andrew J., Parmar Kush, 5AM Opportunities I, L.P., 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Partners VI, LLC, 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC

5AM Ventures VI, L.P.

General Atlantic, L.P.

News Filter

Completion of Acquisition or Disposition of Assets, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Material Modification to Rights of Security Holders, Change of Control, Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Financial Statements or Exhibits

Announces Receipt of Minutes From End-Of-Phase 2 Meeting With the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

To Be Acquired by AstraZeneca

Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension

Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

SEC STAFF LETTER